ALSO NOTED: Clinical Data buys Icoria; EMA recommends Hexavac withdrawal; Nektar future bright; Ambrx names new CEO; Novartis t

> Icoria of Research Triangle Park, N.C. has been bought by Clinical Data for $12.5 million. Icoria has been cutting staff and sold its agricultural division to Monsanto last March. Report [1]

> The European Medicines Agency has recommended that Sanofi-Aventis' vaccine Hexavac should be withdrawn. Story [2]

> The San Francisco Business Times profiles San Carlos, Ca.-based Nektar which expects its inhaled insulin to become a blockbuster. The company is planning for future products using its drug delivery technology. Article [3]

> Chutes & Ladders: Ambrx has named Martin Mattingly, Pharm.D. as president and CEO. Release [4]

> Novartis announced that a recent trial showed that its once-a-day asthma treatment works quickly and lasts for 24 hours. Story [5]

> Vyteris is touting positive results for an early-stage trial of its Actyve transdermal drug technology. Release [6]

> AstraZeneca says that the FDA has given full approval for the use of Arimidex for breast cancer in post-menopausal women whose cancer has not spread. Story [7]

> Roche Holding and GlaxoSmithKline have received European Union marketing approval for Bonviva, a treatment for post-menopausal osteoporosis. Article [8]

And finally…A standard therapy for sleep apnea appears to work well as a treatment for depression. Article [9]